Charles River Acquires Cerebricon Ltd.

Charles River (NYSE:CRL) has acquired Cerebricon Ltd. in Kuopio, Finland, for USD 9 million. Cerebricon provides pharmaceutical discovery services foused on the central nervous system (CNS) diseases category.